The Dermatology Digest

JUNE 14, 2024

The late-breaking data, presented at the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois, showed that upadacitinib bested dupilumab for all ranked secondary endpoints of LEVEL-UP, including complete skin clearance and rapid resolution of itching in patients with severe itch.

Dermatitis 36

Dermatitis Eczema Therapy Clinic 36

The Dermatology Digest

FEBRUARY 26, 2024

2 In this review, we highlight the “epithelial barrier hypothesis” proposed by Akdis, discuss the important roles of the skin, gut, and respiratory barriers, and discuss novel therapies. Impairment in tight junction expression has been shown to contribute to the barrier dysfunction observed in patients with atopic dermatitis.

Dermatitis 74

Dermatitis Irritation Therapy Dermatology 74

The Dermatology Digest

FEBRUARY 8, 2024

This will be a game-changer if it pans out and may get us closer to disease cures via optimization of existing biological therapies,” he says. New systemic agents and even new concepts in the prevention of atopic dermatitis and the microbiome seem just around the corner too, Dr. Lio says. “We And the Skin Disease of the Year Is….

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

The Dermatology Digest

JULY 10, 2024

for use in moderate to severe atopic dermatitis (AD) in the NHS England. The interleukin-13 blocker is indicated for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate to severe AD, who are candidates for systemic therapy.

Dermatitis 36

Dermatitis Safety Dermatology Marketing 36

The Dermatology Digest

FEBRUARY 1, 2024

Atopy patch tests (APTs) may be the best way to detect food‐triggered atopic dermatitis (AD), according to a new literature review in Clinical Reviews in Allergy & Immunology. APTs detect sensitization to food proteins responsible for systemic contact dermatitis (SCD), which can then be confirmed by oral food challenge.

Dermatitis 36

Dermatitis Eczema Medical Therapy 36

The Dermatology Digest

JUNE 14, 2024

Food and Drug Administration (FDA) has cleared InnoCare Pharma’s investigational new drug application (IND) for ICP-332, a tyrosine kinase 2 (TYK2) inhibitor that’s being studied in moderate to severe atopic dermatitis (AD). Currently, no TYK2 inhibitors have obtained marketing approval for the treatment of AD.

Dermatitis 36

Dermatitis Marketing Safety Innovations 36

The Dermatology Digest

MARCH 11, 2024

Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine and a partner at Medical Dermatology Associates of Chicago, discusses which ones works best.

Dermatitis 69

Dermatitis Eczema Dermatology Pharmaceutical 69

The Dermatology Digest

MAY 2, 2024

Aslan and Zenyaku are teaming up to explore how eblasakimab’s mechanism of action differs from that of other biologic therapies for atopic dermatitis (AD). This new agreement expands upon the commercial agreement that Aslan signed with Zenyaku in June 2023 for the development and commercialization of eblasakimab in Japan.

Pharmaceutical 74

Pharmaceutical Dermatitis Office Clinic 74

The Dermatology Digest

AUGUST 13, 2024

Nemolizumab was granted Breakthrough Therapy Designation in December 2019 and Priority Review in February 2024 by the U.S. The phase III OLYMPIA 1 and OLYMPIA 2 clinical trials evaluated the efficacy and safety of nemolizumab administered subcutaneously every four weeks in more than 500 patients with prurigo nodularis.

Dermatitis 36

Dermatitis Safety Clinic Dermatology 36

The Dermatology Digest

MARCH 9, 2024

Raj Chovatiya, MD, PhD, Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago, discusses the role that abrocitinib (Cibinqo, Pfizer) and upadacitinib (Rinvoq, AbbVie) play in treating patients with atopic dermatitis (AD). Watch Now Biosimilars in Dermatology: Where Do They Fit in?

Dermatitis 36

Dermatitis Eczema Dermatology Clinic 36

The Dermatology Digest

MARCH 9, 2024

Raj Chovatiya, MD, PhD, Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago, discusses the role that abrocitinib (Cibinqo, Pfizer) and upadacitinib (Rinvoq, AbbVie) play in treating patients with atopic dermatitis (AD). Watch Now Biosimilars in Dermatology: Where Do They Fit in?

Dermatitis 36

Dermatitis Eczema Dermatology Clinic 36

The Dermatology Digest

FEBRUARY 12, 2024

Alys believes that emerging indications such as atopic dermatitis, vitiligo, alopecia areata and chronic spontaneous urticaria, will see the next breakthroughs in dermatological advancements.

Pharmaceutical 74

Pharmaceutical Technology Dermatology Medical 74

The Dermatology Digest

FEBRUARY 16, 2024

for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy. In addition to CSU, dupilumab is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and prurigo nodularis.

Pharmaceutical 36

Pharmaceutical Safety Dermatitis Therapy 36

First Derm

DECEMBER 4, 2023

Dry skin is a very common problem in people with atopic dermatitis, a chronic inflammatory skin condition characterized by patches of itchy, dry, red, and inflamed skin. Atopic dermatitis (eczema) characterized by itchy patches of red, inflamed, dry skin. Therapeutic implications of a barrier-based pathogenesis of atopic dermatitis.

Dry Skin 92

Dry Skin Moisturization Eczema Dermatitis 92

Aesthetics Advisor

OCTOBER 3, 2023

Doctors were confronted with a problem: some people simply didn't respond to the investigational treatment, which was offered after standard therapy failed. Strategies to enhance natural killer cell survival and function are needed to improve clinical efficacy. Without treatment, which is simply providing niacin, pellegra can be fatal.

Therapy 36

Therapy Innovations Clinic Dermatitis 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

DECEMBER 18, 2023

Air pollution may contribute to the development or worsening of skin conditions such as atopic dermatitis and eczema, according to researchers out of Massachusetts General Hospital (MGH). Carbon monoxide concentrations that were an average of 0.22 ppm in the months of May–September in 2019–2022 rose to 0.6 ppm in July of 2023.

Eczema 36

Eczema Dermatitis Hospital Dermatology 36

Lipgloss and Aftershave

SEPTEMBER 3, 2024

Douglas Preston, LE, creator of the Preston Comedone Extractor and a pioneer in acne therapy. Nikki Mann, LE, a clinical esthetician specializing in result-based treatments. Facial Contact Dermatitis with Rajani Katta, MD Case-based reviews of common presentations, allergens, and treatment strategies.

Education 52

Education Esthetician Medical Esthetics 52

First Derm

JULY 2, 2024

Online Dermatologist Sweating and Eczema: How to Manage Flare-Ups Eczema and Sweat | Symptoms of eczema | Physiology | How Sweating Affects Eczema | Triggers for Eczema | Related conditions | Managing Sweat to Prevent Eczema Flare-Ups | Treatment Key Takeaways Eczema, particularly atopic dermatitis, flares up with triggers like sweat.

Eczema 59

Eczema Management Dermatitis Irritation 59

The Dermatology Digest

MARCH 11, 2024

Atopic dermatitis (AD) is extremely common, but it can resemble psoriasis, urticaria, non-blistering immunobolus disease, cutaneous lymphoma, and many other skin conditions. Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Watch Now The Lowdown on Molluscum Nanette B.

Dermatitis 36

Dermatitis Eczema Dermatology Pharmaceutical 36

The Dermatology Digest

JANUARY 29, 2024

Food and Drug Administration approvals in dermatology from Cabtreo for acne and two new therapies for molluscum contagiosum to secukinumab (Cosentyx, Novartis) for hidradenitis suppurativa, and a new device to aid melanoma diagnosis, plus more. Watch Now Embracing Combination Therapy in Rosacea Julie C. Watch Now What is Urticaria?

Rosacea 36

Rosacea Dermatitis Hospital Dermatology 36

The Dermatology Digest

DECEMBER 18, 2023

New practice parameters from the Joint Task Force for Practice Parameter) recommend the use of topical corticosteroids or topical calcineurin inhibitors in patients with uncontrolled atopic dermatitis (AD) despite moisturizer use. Suggest the usage of crisaborole 2% ointment for mild to moderate atopic dermatitis. in a news release. “It

Dermatitis 36

Dermatitis Partnerships Therapy Safety 36

The Dermatology Digest

JUNE 26, 2024

chief of NIAID’s Laboratory of Clinical Immunology & Microbiology Epithelial Research Unit, found specific strains of R. mucosa in the laboratory, conducted preclinical (laboratory/animal) and clinical (human) studies, and made the bacteria available for commercial, non-therapeutic development. mucosa therapy.

Eczema 74

Eczema Clinic Therapy Management 74

The Dermatology Digest

JANUARY 7, 2024

Led by Louisville, KY dermatologist Joe Fowler, MD, and George Martin, MD, a dermatologist in Kihei, HI, and Maui Derm Program Chairman, the four-day meeting will feature treatment updates on psoriasis, atopic dermatitis, acne/rosacea, pigmentation disorders, blistering diseases, pediatric dermatology and more. Surgeon General Boris D.

Dermatitis 36

Dermatitis Dermatology Rosacea Hospital 36

The Dermatology Digest

MARCH 10, 2024

Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine and a partner at Medical Dermatology Associates of Chicago, shares pearls on keeping pediatric patients comfortable during common dermatologic procedures. From distraction techniques to pharmacologic measures, Peter A.

Dermatology 36

Dermatology Dermatitis Eczema Clinic 36

The Dermatology Digest

MARCH 9, 2024

Mark Lebwohl, MD, Dean for Clinical Therapeutics and Waldman Professor and Chairman of the Kimberly and Eric J. Mark Lebwohl, MD, Dean for Clinical Therapeutics and Waldman Professor and Chairman of the Kimberly and Eric J. The biosimilars are here with even more coming down the pike.

Dermatology 36

Dermatology Dermatitis Eczema Clinic 36

The Dermatology Digest

MARCH 9, 2024

Watch Now Welcome to the Golden Age of Pediatric Dermatology Elizabeth Swanson, MD Elizabeth (Lisa) Swanson, MD, a pediatric dermatologist in Boise, ID, discusses advances in treating kids with atopic dermatitis, psoriasis, vitiligo, alopecia areata, and hemangiomas. Watch Now Biosimilars in Dermatology: Where Do They Fit in?

Dermatitis 36

Dermatitis Eczema Dermatology Clinic 36

The Dermatology Digest

MARCH 9, 2024

Watch Now Welcome to the Golden Age of Pediatric Dermatology Elizabeth Swanson, MD Elizabeth (Lisa) Swanson, MD, a pediatric dermatologist in Boise, ID, discusses advances in treating kids with atopic dermatitis, psoriasis, vitiligo, alopecia areata, and hemangiomas. Watch Now Biosimilars in Dermatology: Where Do They Fit in?

Eczema 36

Eczema Dermatitis Dermatology Clinic 36

The Dermatology Digest

MARCH 11, 2024

In addition, results from the phase III ARCADIA clinical trials in atopic dermatitis (AD) found that nemolizumab-treated patients who responded at 16 weeks maintained skin and itch responses through to week 48, even when dosing was reduced from every four to every eight weeks. No new safety signals were observed in this trial.

Dermatitis 36

Dermatitis Safety Dermatology Eczema 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 28

Eczema Dermatitis Safety Therapy 28

First Derm

APRIL 5, 2024

Ensuring adherence to therapies in dermatology is paramount for enhancing treatment efficacy and promoting patient well-being. Side Effects of Topical Treatments: Topical acne therapies may be discontinued or used incorrectly due to side effects like erythema, irritation, itching, and desquamation, reducing their therapeutic efficacy.

Dermatology 59

Dermatology Treatments Education Medical 59

The Dermatology Digest

MARCH 11, 2024

Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine and a partner at Medical Dermatology Associates of Chicago, discusses which ones works best.

Dermatitis 36

Dermatitis Eczema Dermatology Pharmaceutical 36

The Dermatology Digest

MARCH 11, 2024

Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine and a partner at Medical Dermatology Associates of Chicago, discusses which ones works best.

Dermatitis 36

Dermatitis Eczema Dermatology Pharmaceutical 36

The Dermatology Digest

MARCH 10, 2024

Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine and a partner at Medical Dermatology Associates of Chicago, discusses which ones works best.

Treatments 36

Treatments Dermatitis Eczema Dermatology 36

The Dermatology Digest

MARCH 10, 2024

Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine and a partner at Medical Dermatology Associates of Chicago, discusses which ones works best.

Treatments 36

Treatments Pharmaceutical Dermatitis Eczema 36

Aesthetics Advisor

MARCH 10, 2024

Randomized, double-blind, controlled trials suggest that excluding certain foods, such as eggs and chicken, can significantly improve atopic dermatitis. Eczema, also known as atopic dermatitis, is a chronic inflammatory skin disease. Atopic dermatitis. In adults, it may increase the risk of major depression. Anc Sci Life.

Eczema 36

Eczema Diet Dermatitis Document 36